Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

37.82
-0.9300-2.40%
Volume:528.06K
Turnover:19.97M
Market Cap:7.81B
PE:-13.42
High:38.30
Open:38.18
Low:37.53
Close:38.75
52wk High:45.42
52wk Low:14.58
Shares:206.40M
Float Shares:89.57M
Volume Ratio:0.58
T/O Rate:0.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:10.61
PE(LYR):-13.65

Loading ...

Immunovant Announces Annual Shareholder Meeting

Reuters
·
Jul 23

Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million

Reuters
·
Jul 07

Chief Technology Officer Of Immunovant Sold 53% Of Their Shares

Simply Wall St.
·
Jul 02

Immunovant is Maintained at Buy by Citigroup

Dow Jones
·
Jul 01

Immunovant price target raised to $61 from $57 at Citi

TIPRANKS
·
Jun 30

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015

Reuters
·
Jun 27

Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million

Reuters
·
Jun 27

S&P 500 Futures Drop in Premarket Trading; on Semiconductor, Davita Lag

Dow Jones
·
Jun 26

Immunovant (IMVT) Is Up 7.5% After Batoclimab Shows Phase IIb CIDP Benefit - What's Changed

Simply Wall St.
·
Jun 19

Immunovant director Atul Pande disposes of USD 51,030 common shares

Reuters
·
Jun 17

A Look At Immunovant (IMVT) Valuation As IMVT 1402 Trial Engagement Lifts Investor Interest

Simply Wall St.
·
Jun 11

Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?

Simply Wall St.
·
Jun 08

Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million

Reuters
·
May 30

Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
May 30

Immunovant Is Maintained at Buy by Guggenheim

Dow Jones
·
May 26

H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)

TIPRANKS
·
May 26

Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million

Reuters
·
May 23

Immunovant Is Maintained at Hold by Truist Securities

Dow Jones
·
May 22

Immunovant price target raised to $30 from $23 at Truist

TIPRANKS
·
May 22

Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications

TIPRANKS
·
May 22